


Insider Trading - Cooper Ronald Harold Wilfred - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Cooper Ronald Harold Wilfred





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-11-03Option Award
2016-11-076:38 pm
N/AN/A
Albireo Pharma Inc
ALBO
Cooper Ronald Harold WilfredPresident and CEODirector
5,946
$0
155,381(Direct)
View


2016-11-03Option Award
2016-11-076:38 pm
N/A2026-04-14
Albireo Pharma Inc
ALBO
Cooper Ronald Harold WilfredPresident and CEODirector
155,381
$1
155,381(Direct)
View


2016-11-03Option Award
2016-11-076:38 pm
N/A2026-04-14
Albireo Pharma Inc
ALBO
Cooper Ronald Harold WilfredPresident and CEODirector
19,422
$1
155,381(Direct)
View


2016-06-07Option Award
2016-06-104:25 pm
2019-06-072026-06-07
Genocea Biosciences Inc
GNCA
Cooper Ronald Harold WilfredDirector
25,000
$4.64
25,000(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Fri, 28 Jul 2017 05:13:20 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  








    Ron Cooper | Albireo Pharma, Inc. | ZoomInfo.com


Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft




















 




Ronald Harold Wilfred  Cooper - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











Ronald Harold Wilfred  Cooper
Check out list of companies and businesses related to Ronald Harold Wilfred  Cooper. Find out Ronald Harold Wilfred  Cooper address and contact details. View other people related to Ronald Harold Wilfred  Cooper - coworkers, colleagues, companions, etc.
Address:   

C/O GENOCEA BIOSCIENCES, INC. 100 ACORN PARK DRIVE 5TH FLOOR CAMBRIDGE 02410 MA




Companies related to Ronald Harold Wilfred  Cooper
CIKCompany NamePositionCompany Address0001322505ALBIREO PHARMA, INC.President and CEO 10 POST OFFICE SQUARE SUITE 502 SOUTH BOSTON 021090001457612GENOCEA BIOSCIENCES, INC.Director 100 ACORN PARK DRIVE  CAMBRIDGE 02140




Ronald Harold Wilfred  Cooper on the Web
Persons related to Ronald Harold Wilfred  Cooper - ALBIREO PHARMA, INC.NamePositionCityKrasner  AlanDanburyAB  ASTRAZENECASODERTALJEPLC  ASTRAZENECALONDONGinsberg  BarryDanburyPaul S  BavierGeneral Counsel DANBURYPaul S  BavierGeneral Counsel DANBURYPaul S  BavierGeneral Counsel/Corp. Sec. DANBURYPaul S  BavierGeneral Counsel DANBURYPaul S  BavierGeneral Counsel/Corp. Sec. DANBURYDAVID  BONDERMANPereira  BrianDanburyJULIA R  BROWNDirector SAN DIEGOJULIA R  BROWNDirector DANBURYMARTHA J  CARTERChief Regulatory Officer MORRISTOWNDonald M Jr.  CaseyDirector DANBURYALBERT  CHADirector DANBURYALBERT  CHADirector DANBURYDavid  ChiswellDirector BOSTONRonald Harold Wilfred  CooperPresident and CEO CAMBRIDGEJAMES G  COULTERFORTH WORTHLorber  DanielDanburyScoon  DaveyDanburyERROL B  DESOUZACEO ERROL B  DESOUZACEO DANBURYERROL B  DESOUZACEO DANBURYERROL B  DESOUZACEO DANBURYERROL B  DESOUZACEO DANBURYERROL B  DESOUZACEO and President DANBURYERROL B  DESOUZACEO DANBURYSteiner  ErikDanburyDe Souza  ErrolDanburyROBERT  FELDSTEINVice President DANBURYROBERT  FELDSTEINVice President/ Patents IP DANBURYGary G  GemignaniChief Financial Officer DANBURYMichel  GerardDanburyBarry H  GinsbergDirector DANBURYBarry H  GinsbergDirector DANBURYGREAT POINT PARTNERS I LP10% Owner GREENWICHGREAT POINT PARTNERS I LP10% Owner GREENWICHGREAT POINT PARTNERS I LP10% Owner GREENWICHGREAT POINT PARTNERS I LP10% Owner GREENWICHGREAT POINT PARTNERS I LP10% Owner GREENWICHGREAT POINT PARTNERS LLCGREENWICHMichael  GutchDirector BOSTONLieberman  IraDanburySAMUEL D  ISALYNEW YORKBrown  JulieDanburyAlan Seth  KrasnerChief Medical Officer DANBURYAlan Seth  KrasnerChief Medical Officer DANBURYAlan Seth  KrasnerChief Medical Officer DANBURYAlan Seth  KrasnerChief Medical Officer DANBURYDAVID  KROINDirector DANBURYDAVID  KROINDirector DANBURYDAVID  KROINDirector DANBURYIRA  LIEBERMANDirector DANBURYIRA  LIEBERMANDirector DANBURYIRA  LIEBERMANDirector DANBURYDANIEL  LORBERDirector DANBURYDANIEL  LORBERDirector DANBURYJan  MattssonChief Operating Officer BOSTONAlastair  McKinnonEDINBURGHGERARD J  MICHELCFO, VP of Corp and Dev/Treas DANBURYGERARD J  MICHELCFO, VP of Corp Dev and Treas. DANBURYGERARD J  MICHELCFO, VP of Corp and Dev/Treas DANBURYArlene  MorrisDirector SAN DIEGOORBIMED ADVISORS LLC10% Owner NEW YORKORBIMED ADVISORS LLCDirector NEW YORKBavier  PaulDanburyBrian JG  PereiraDirector DANBURYBrian JG  PereiraDirector DANBURYBrian JG  PereiraDirector DANBURYANDREAS  PFUTZNERChief Medical Officer DANBURYANDREAS  PFUTZNERChief Medical Officer in Europ DANBURYPhase4 Partners LtdEDINBURGHPHASE4 VENTURES III GENERAL PARTNER LtdEDINBURGHPHASE4 VENTURES III GP LPEDINBURGHPHASE4 VENTURES III LPEDINBURGHRODERIKE  POHLDANBURYRODERIKE  POHLVP Research DANBURYRODERIKE  POHLVP Research DANBURYRODERIKE  POHLVice President Research DANBURYDenise  Pollard-KnightDirector CAMBRIDGEHeather  PrestonDirector FORT WORTHF SCOTT  REDINGChief Financial Officer DANBURYCHARLES A  SANDERSDirector DANBURYCHARLES A  SANDERSDirector DANBURYCHARLES A  SANDERSDirector DANBURYCHARLES A  SANDERSCHAPEL HILLDAVEY  SCOONDirector BEDFORDDAVEY  SCOONDirector DANBURYPAUL J  SEKHRIDANBURYCharles  SermonEDINBURGHThomas A.  SheaCFO and Treasurer BOSTONParesh  SoniChief Medical Officer MYSTICERIK  STEINERVice President, Operations DANBURYERIK  STEINERVice-President, Operations DANBURYERIK  STEINERVice-President, Operations DANBURYERIK  STEINERVice-President, Operations DANBURYSolomon  SteinerPresident & CEO DANBURYSolomon  SteinerDirector DANBURYSolomon  SteinerDirector DANBURYSTEINER VENTURES LLCMT. KISCOSTEINER VENTURES LLC10% Owner DANBURYTPG Group Holdings (SBS) Advisors, Inc.FORT WORTHJ ARTHUR  URCIUOLIDirector DANBURYJ ARTHUR  URCIUOLIDirector DANBURYVivo Ventures V, LLC10% Owner PALO ALTOR TIMMIS  WARECorp. Secy and General Counsel DANBURYR TIMMIS  WARECorp. Secy and General Counsel DANBURYSCOTT  WEISMANDirector DANBURYSCOTT  WEISMANDirector DANBURYSamuel P  WertheimerDirector NEW YORKSamuel P  WertheimerDirector DANBURYSamuel P  WertheimerDirector DANBURYPeter A  ZornChief Corp. Officer, GC & Sec WINSTON-SALEMPersons related to Ronald Harold Wilfred  Cooper - GENOCEA BIOSCIENCES, INC.NamePositionCityXAVIER  ASISHCAMBRIDGEKENNETH  BATEDirector CAMBRIDGE,KENNETH  BATEDirector CAMBRIDGEKevin  BittermanDirector WALTHAMKatrine  BosleyDirector CAMBRIDGEWilliam D  ClarkPresident and CEO ROCKVILLEWilliam D  ClarkPresident and CEO CAMBRIDGEWilliam D  ClarkPresident and CEO CAMBRIDGERonald Harold Wilfred  CooperDirector CAMBRIDGEEINHORN  DALTONCAMBRIDGERobert E  Farrell JrVP of Finance & Administration CAMBRIDGEJessica Baker  FlechtnerChief Scientific Officer CAMBRIDGEJessica Baker  FlechtnerSr. VP of Research CAMBRIDGESIBER  GEORGECAMBRIDGESIBER  GEORGECAMBRIDGESimeon  GeorgeDirector CONSHOHOCKENPaul  GiannascaVP of Development CAMBRIDGEPaul  GiannascaVP of Development CAMBRIDGEPLC  GLAXOSMITHKLINE BRENTFORD MIDDLESEXSETH V  HETHERINGTONChief Medical Officer ALPHARETTASETH V  HETHERINGTONCAMBRIDGESETH V  HETHERINGTONChief Medical Officer CAMBRIDGEMichael J  HigginsDirector CAMBRIDGEEric S  HoffmanChief Business Officer CAMBRIDGESTEPHEN J  HOFFMANDirector CARLISLESTEPHEN J  HOFFMANDirector WALTHAMFLECHTNER  JESSICACAMBRIDGEFLECHTNER  JESSICACAMBRIDGEJOHNSON & JOHNSON10% Owner NEW BRUNSWICKJOHNSON & JOHNSON DEVELOPMENT CORP ET ALNEW BRUNSWICKBOSLEY  KATRINECAMBRIDGEBITTERMAN  KEVINCAMBRIDGEBITTERMAN  KEVINCAMBRIDGECHEN  LEONCAMBRIDGELux Capital Management, LLC NEW YORKLux Venture Associates II, LLCNEW YORKLux Venture Partners II, L.P.NEW YORKLux Ventures II, L.P.NEW YORKLux Ventures II Sidecar II LLCNEW YORKLux Ventures II Sidecar LPNEW YORKHoward  MayerDirector CAMBRIDGEGIANNASCA  PAULCAMBRIDGEGIANNASCA  PAULCAMBRIDGEPolaris Venture Management Co. V, L.L.C.10% Owner WALTHAMPolaris Venture Management Co. V, L.L.C.10% Owner WALTHAMPolaris Venture Management Co. V, L.L.C.10% Owner WALTHAMPolaris Venture Partners Entrepreneurs' Fund V, L.P.WALTHAMPolaris Venture Partners Entrepreneurs' Fund V, L.P.WALTHAMPolaris Venture Partners Entrepreneurs' Fund V, L.P.WALTHAMPolaris Venture Partners Founders' Fund V, L.P.WALTHAMPolaris Venture Partners Founders' Fund V, L.P.WALTHAMPolaris Venture Partners Founders' Fund V, L.P.WALTHAMPolaris Venture Partners Special Founders' Fund V, L.P.WALTHAMPolaris Venture Partners Special Founders' Fund V, L.P.WALTHAMPolaris Venture Partners Special Founders' Fund V, L.P.WALTHAMPolaris Venture Partners V, L.P.WALTHAMPolaris Venture Partners V, L.P.WALTHAMPolaris Venture Partners V, L.P.WALTHAMJonathan  PooleChief Financial Officer CAMBRIDGEVENKATARAMANI  RAVICAMBRIDGEFARRELL JR.  ROBERTCAMBRIDGEFARRELL JR.  ROBERTCAMBRIDGEPAULL  ROBERTCAMBRIDGEPAULL  ROBERTCAMBRIDGEHETHERINGTON  SETHCAMBRIDGEGeorge  SiberDirector NEW YORKGEORGE  SIMEONCAMBRIDGEGEORGE  SIMEONCAMBRIDGEHOFFMAN  STEPHENCAMBRIDGEHOFFMAN  STEVECAMBRIDGERavichandran  VenkataramaniCAMBRIDGECLARK  WILLIAMCAMBRIDGECLARK  WILLIAMCAMBRIDGE












 








Genocea Biosciences Inc. (via Public) / cooper ronald harold wilfred



























                        Hello .
                    


 United States 







News


International News


Education


Environment


Healthcare


Technology


Internet




Science


Social and Non-Profit


Local News




Politicsand Policy


Government


Politics


Local Government


International Policy




Businessand Economy


Economy


Finance


Stock Markets




Jobs and Labor


Company News


Industry News


Aerospace


Agriculture


Chemicals


Commodities


Construction


Consumer Electronics


Defense


Energy


Nuclear Energy


Oil and Gas


Renewable Energy




Financial Services


Banking


Insurance




Fishing and Aquaculture


Manufacturing


Information Technology


Metals and Mining


Pharmaceuticals and Biotechnology


Real Estate


Professional and Business Services


Legal




Telecommunications


Tobacco


Retail


Transportation


Air Transportation


Maritime Transportation


Rail Transportation


Road Transportation




Utilities


Forestry and Wood Industry






Artsand Culture


Art


Books and Literature


Entertainment


Cinema


Media


Radio and Television




Music






Lifestyleand Leisure


Automotive


Home and Garden


Fashion and Luxury


Clothing and Textile




Food


Travel and Hospitality


Boating and Yachting




Sports


Baseball


Basketball


Boxing


Cricket


Cycling


Football (American)


Football (Australian)


Football (Soccer)


Golf


Hockey


Racing


Rugby


Sailing


Skiing and Winter Sports


Tennis


Volleyball











noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.
To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.
If you have changed your browser's security settings, you can click here.






related announcements
Company News


CommScope Holding Company Inc.
We Need to Stop Thinking “Not in My Backyard”


ArcBest Corporation
ArcBest Announces Second Quarter 2017 Results


Dril-Quip Inc.
Dril-Quip, Inc. Announces Results for Second Quarter 2017


More
Financial Services


Sabra Health Care REIT Inc.
Sabra Health Care REIT Files Investor Presentation


MEDNAX Inc.
MEDNAX Reports Second Quarter GAAP EPS of $0.69


NASDAQ Inc.
Redfin (Nasdaq: RDFN) to Ring The Nasdaq Stock Market Opening Bell in[...]


More











search





















Genocea Biosciences Inc.



06/14/2016 | Press release | Distributed by Public on 06/14/2016 14:44
cooper ronald harold wilfred











FORM 3







OMB APPROVAL 
OMB Number: 3235-0104 
Estimated average burden
             hours per response... 0.5
















1. Name and Address of Reporting Person 

Cooper Ronald Harold Wilfred



2. Date of Event Requiring Statement (MM/DD/YYYY) 


3. Issuer Name and Ticker or Trading Symbol

GENOCEA BIOSCIENCES, INC. [GNCA]






C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR



4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director _____ 10% Owner 
_____ Officer (give title below) _____ Other (specify below) 





CAMBRIDGE, MA 02410



5. If Amendment, Date Original Filed (MM/DD/YYYY) 



6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
               ___ Form filed by More than One Reporting Person












1.Title of Security
               (Instr. 4)


2. Amount of Securities Beneficially Owned
               (Instr. 4)


3. Ownership Form: Direct (D) or Indirect (I)
               (Instr. 5)


4. Nature of Indirect Beneficial Ownership
               (Instr. 5)












1. Title of Derivate Security
               (Instr. 4)


2. Date Exercisable and Expiration Date
(MM/DD/YYYY)


3. Title and Amount of Securities Underlying Derivative Security
               (Instr. 4)


4. Conversion or Exercise Price of Derivative Security


5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
               (Instr. 5)


6. Nature of Indirect Beneficial Ownership
               (Instr. 5)




Date Exercisable


Expiration Date


Title


Amount or Number of Shares








Explanation of Responses:







Remarks: 
            Exhibit List - Exhibit 24 Power of Attorney
          





            No securities are beneficially owned.
          






Reporting Owners 




Reporting Owner Name / Address






Director


10% Owner


Officer


Other




Cooper Ronald Harold Wilfred
             C/O GENOCEA BIOSCIENCES, INC.
             100 ACORN PARK DRIVE 5TH FLOOR
             CAMBRIDGE, MA 02410


X













Signatures 




/s/ Jonathan Poole, Attorney-in-Fact




6/14/2016




Signature of Reporting Person


Date









Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.




*


If the form is filed by more than one reporting person, see Instruction 5(b)(v).




**


Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).




Note:


File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.




Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
















Sharing and Personal Tools

Please select the service you want to use:

Newsvine
Digg
Delicious
StumbleUpon
Technorati
Buzz
Favorites
Google Reader





Public link

Please use the above public link if you want to share this noodl on another website.


Close





Smartlinks
| Genocea Biosciences Inc.
| Company News
| Business Announcements
| Financial Services
| Research Firms and Institutes
| Nasdaq
| Börse Frankfurt
| Börse Berlin




 Back


 View original format











Copyright ©2006-2017 Public Technologies Inc.  | 
Privacy Policy | Terms of Use | Contact






Genocea Biosciences Inc. (via Public) / cooper, ronald harold wilfred



























                        Hello .
                    


 United States 







News


International News


Education


Environment


Healthcare


Technology


Internet




Science


Social and Non-Profit


Local News




Politicsand Policy


Government


Politics


Local Government


International Policy




Businessand Economy


Economy


Finance


Stock Markets




Jobs and Labor


Company News


Industry News


Aerospace


Agriculture


Chemicals


Commodities


Construction


Consumer Electronics


Defense


Energy


Nuclear Energy


Oil and Gas


Renewable Energy




Financial Services


Banking


Insurance




Fishing and Aquaculture


Manufacturing


Information Technology


Metals and Mining


Pharmaceuticals and Biotechnology


Real Estate


Professional and Business Services


Legal




Telecommunications


Tobacco


Retail


Transportation


Air Transportation


Maritime Transportation


Rail Transportation


Road Transportation




Utilities


Forestry and Wood Industry






Artsand Culture


Art


Books and Literature


Entertainment


Cinema


Media


Radio and Television




Music






Lifestyleand Leisure


Automotive


Home and Garden


Fashion and Luxury


Clothing and Textile




Food


Travel and Hospitality


Boating and Yachting




Sports


Baseball


Basketball


Boxing


Cricket


Cycling


Football (American)


Football (Australian)


Football (Soccer)


Golf


Hockey


Racing


Rugby


Sailing


Skiing and Winter Sports


Tennis


Volleyball











noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.
To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.
If you have changed your browser's security settings, you can click here.






related announcements
Finance


CommScope Holding Company Inc.
We Need to Stop Thinking “Not in My Backyard”


ArcBest Corporation
ArcBest Announces Second Quarter 2017 Results


Dril-Quip Inc.
Dril-Quip, Inc. Announces Results for Second Quarter 2017


More
Company News


Sabra Health Care REIT Inc.
Sabra Health Care REIT Files Investor Presentation


Tenneco Inc.
Tenneco Reports Second Quarter 2017 Results


Ascent Solar Technologies Inc.
Ascent Solar Demonstrates Breadth of Capabilities at the US Special[...]


More











search





















Genocea Biosciences Inc.



06/10/2016 | Press release | Distributed by Public on 06/10/2016 14:40
cooper, ronald harold wilfred











FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 


UNITED STATES SECURITIES AND EXCHANGE COMMISSION
             Washington, D.C. 20549 


OMB APPROVAL 
OMB Number: 3235-0287 
Estimated average burden
             hours per response... 0.5
















1. Name and Address of Reporting Person  Cooper Ronald Harold Wilfred


2. Issuer Name and Ticker or Trading Symbol GENOCEA BIOSCIENCES, INC. [ GNCA ]


5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director _____ 10% Owner 
_____ Officer (give title below) _____ Other (specify below) 




C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR


3. Date of Earliest Transaction (MM/DD/YYYY)




CAMBRIDGE, MA 02410


4. If Amendment, Date Original Filed (MM/DD/YYYY)


6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person
             ___ Form filed by More than One Reporting Person











1.Title of Security
               (Instr. 3)


2. Trans. Date


2A. Deemed Execution Date, if any


3. Trans. Code
               (Instr. 8)


4. Securities Acquired (A) or Disposed of (D)
               (Instr. 3, 4 and 5)


5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
               (Instr. 3 and 4)


6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)


7. Nature of Indirect Beneficial Ownership (Instr. 4)




Code


V


Amount


(A) or (D)


Price












1. Title of Derivate Security
               (Instr. 3)


2. Conversion or Exercise Price of Derivative Security


3. Trans. Date


3A. Deemed Execution Date, if any


4. Trans. Code
               (Instr. 8)


5. Number of Derivative Securities Acquired (A) or Disposed of (D)
               (Instr. 3, 4 and 5)


6. Date Exercisable and Expiration Date


7. Title and Amount of Securities Underlying Derivative Security
               (Instr. 3 and 4)


8. Price of Derivative Security
               (Instr. 5)


9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)


10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)


11. Nature of Indirect Beneficial Ownership (Instr. 4)




Code


V


(A)


(D)


Date Exercisable


Expiration Date


Title


Amount or Number of Shares






Stock Option (Right to Buy) 


$4.64 


6/7/2016 




A 




25000




6/7/2019 


6/7/2026 


Common Stock 


25000.0 


$0 


25000 


D 










Explanation of Responses:




( 1) 


The option vests annually in equal installments over a three-year period beginning on the date of grant.







Reporting Owners 




Reporting Owner Name / Address






Director


10% Owner


Officer


Other




Cooper Ronald Harold Wilfred
             C/O GENOCEA BIOSCIENCES, INC.
             100 ACORN PARK DRIVE 5TH FLOOR
             CAMBRIDGE, MA 02410


X













Signatures 




/s/ Jonathan Poole, Attorney-in-Fact




6/10/2016




Signature of Reporting Person


Date







Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.




*


If the form is filed by more than one reporting person, see Instruction 4(b)(v).




**


Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).




Note:


File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.




Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
















Sharing and Personal Tools

Please select the service you want to use:

Newsvine
Digg
Delicious
StumbleUpon
Technorati
Buzz
Favorites
Google Reader





Public link

Please use the above public link if you want to share this noodl on another website.


Close





Smartlinks
| Genocea Biosciences Inc.
| Finance
| Derivative Securities
| Company News
| Directors Dealing and Insider Transactions
| Financial Services
| Research Firms and Institutes
| Nasdaq
| Börse Frankfurt
| Börse Berlin




 Back


 View original format











Copyright ©2006-2017 Public Technologies Inc.  | 
Privacy Policy | Terms of Use | Contact






Genocea Biosciences : cooper, ronald harold wilfred | 4-Traders















































































 




Log in






E-mail



Password







Remember




Forgot password ?









Become a member for free
Sign up





Sign up




New memberSign up for FREE


New customerDiscover our portfolios












 United States
 United Kingdom
 France
 Deutschland
 Schweiz (DE)
 Suisse (FR)










Settings

            Dynamic quotes 


OFFON








 








Markets
Equities
North AmericaEuropeAsiaOceaniaMiddle East» More Equities

Indexes
DOW JONESS&P 500NASDAQ 100TSX COMPFTSE 100» More Indexes

Currency / Forex
EUR / USDGBP / USDUSD / JPYUSD / CADAUD / USD» More Currencies

Commodities
GOLDCrude Oil (WTI)Crude Oil (BRENT)SILVERPLATINUM» More Commodities


 News
Latest News
CompaniesMarketsEconomyCurrency / ForexCommoditiesInterest RatesBusiness LeadersFinancial calendarEconomic calendar

Listed company
Analyst reco.RumorsIPOsCapital Markets TransactionsNew ContractsProfits warningsAppointmentsPress ReleasesEventsCorporate actions

Sector News
EnergyBasic MaterialsIndustrialsConsumer CyclicalConsumer Non-CyclicalFinancialsHealthcareTechnologyTelecommunications ServicesUtilities


 Analysis
All AnalysisCommentariesIndex AnalysisStock Trading StrategiesCommodity AnalysisForex Analysis

 Stock Picks
All stock picks

 Portfolios
My Portfolio
Virtual portfolios
4-Traders Portfolios
European PortfolioUSA PortfolioAsian Portfolio


 Screeners
Market Screener HomeFundamental Analyse
Top Investor RatingTop Trading RatingTop ConsensusGrowth stocksYield stocksLow valuations

Technical Analysis
Oversold stocksOverbought stocksClose to resistancesClose to supportsAccumulation phaseMost volatile stocks


 Watchlists
My Watchlists
Watchlists
Top Lists
Yield stocksGrowth stocksUndervalued Stocks


 Top / Flop
Top News
Most Read NewsHot News

Top Fundamentals
Top CapitalizationTop YieldTop PERTop ConsensusTop Fundamentals

Top Technicals
Top RSIUnusual volumesTop GapsTop STIM

Top Movers
Top USATop CanadaTop U.K.Top GermanyTop EuropeTop Asia


 Tools
Market ScreenerDynamic chartFinancial calendarEconomic calendarSector researchCurrency converter

 Our Services
Premium AccessDiscover our Services

 



















 







4-Traders Homepage  >  Equities  >  Nasdaq  >  Genocea Biosciences Inc    GNCA










     GENOCEA BIOSCIENCES INC (GNCA)     


Add to my list    

Mes dernières consult.Most popular
Manage my lists

















 







 Delayed  - 07/27 10:00:00 pm

6.09
USD
 
-1.30%










07/25 GENOCEA BIOSCIE : Reports Positive Top-Line 12-Month Phase 2b Data f..


07/25 INSIDER TRADING : GNCA) – CFO Sold 45,000 shares of Stock


07/24 GENOCEA BIOSCIE : current report

 







SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions News SummaryMost relevantAll newsSector newsTweets


















 




Genocea Biosciences : cooper, ronald harold wilfred



































0






06/10/2016 | 10:44pm CEST 


Send by mail :
Last Name :
Name :
From* :
To* :
(You can enter multiple email addresses separated by commas)
Message :
*Required fields








FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
             Washington, D.C. 20549 

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden
             hours per response... 0.5








1. Name and Address of Reporting Person  Cooper Ronald Harold Wilfred


2. Issuer Name and Ticker or Trading Symbol GENOCEA BIOSCIENCES, INC. [ GNCA ]


5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) 

C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR


3. Date of Earliest Transaction (MM/DD/YYYY)


CAMBRIDGE, MA 02410


4. If Amendment, Date Original Filed (MM/DD/YYYY)


6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person
             ___ Form filed by More than One Reporting Person




1.Title of Security
               (Instr. 3)


2. Trans. Date


2A. Deemed Execution Date, if any


3. Trans. Code
               (Instr. 8)


4. Securities Acquired (A) or Disposed of (D)
               (Instr. 3, 4 and 5)


5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
               (Instr. 3 and 4)


6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)


7. Nature of Indirect Beneficial Ownership (Instr. 4)


Code


V


Amount


(A) or (D)


Price




1. Title of Derivate Security
               (Instr. 3)


2. Conversion or Exercise Price of Derivative Security


3. Trans. Date


3A. Deemed Execution Date, if any


4. Trans. Code
               (Instr. 8)


5. Number of Derivative Securities Acquired (A) or Disposed of (D)
               (Instr. 3, 4 and 5)


6. Date Exercisable and Expiration Date


7. Title and Amount of Securities Underlying Derivative Security
               (Instr. 3 and 4)


8. Price of Derivative Security
               (Instr. 5)


9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)


10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)


11. Nature of Indirect Beneficial Ownership (Instr. 4)


Code


V


(A)


(D)


Date Exercisable


Expiration Date


Title


Amount or Number of Shares


Stock Option (Right to Buy) 


$4.64 


6/7/2016 




A 





25000




6/7/2019 


6/7/2026 


Common Stock 


25000.0 


$0 


25000 


D 




Explanation of Responses:


( 1) 


The option vests annually in equal installments over a three-year period beginning on the date of grant.


Reporting Owners 

Reporting Owner Name / Address




Director


10% Owner


Officer


Other


Cooper Ronald Harold Wilfred
             C/O GENOCEA BIOSCIENCES, INC.
             100 ACORN PARK DRIVE 5TH FLOOR
             CAMBRIDGE, MA 02410


X








Signatures 

/s/ Jonathan Poole, Attorney-in-Fact




6/10/2016


Signature of Reporting Person


Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.


*


If the form is filed by more than one reporting person, see Instruction 4(b)(v).


**


Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).


Note:


File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.


Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.




Genocea Biosciences Inc. published this content on 10 June 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on  10 June 2016 20:44:01 UTC.
          


Original documenthttp://ir.genocea.com/secfiling.cfm?filingID=1676880-16-1&CIK=1457612
Public permalinkhttp://www.publicnow.com/view/9DFC133066B27E79666758757F135A058AE49668























































0






 






Latest news on GENOCEA BIOSCIENCES INC




07/25 GENOCEA BIOSCIENCES INC : Todays Research Reports on Trending Tickers: Genocea ..

07/25 GENOCEA BIOSCIENCES : Reports Positive Top-Line 12-Month Phase 2b Data for GEN-0..

07/25 INSIDER TRADING ACTIVITY GENOCEA BIO : GNCA) – CFO Sold 45,000 shares of S..

07/24 GENOCEA BIOSCIENCES : current report

07/24 GENOCEA BIOSCIENCES, INC. (NASDAQ : GNCA) Files An 8-K Regulation FD Disclosure

07/24 GENOCEA BIOSCIENCES : Reports Positive Top-Line 12-Month Phase 2b Data for GEN-0..

07/24 GENOCEA BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and E..

07/24 Genocea Reports Positive Top-Line 12-Month Phase 2b Data for  GEN-003 in Geni..

06/26 Genocea Added to Russell 3000® and Russell 2000® Indices

06/15 GENOCEA BIOSCIENCES : current report



More news




News from SeekingAlpha




07/25 Genocea Biosciences's (GNCA) Conference Call On Positive GEN-003 Phase 2b Res..

07/25 PREMARKET GAINERS AS OF 9 : 05 am

07/24 BIOTECH FORUM DAILY DIGEST : Dynavax Technologies' Moment Of Truth Arrives

07/24 PREMARKET GAINERS AS OF 9 : 05 am

07/24 Genocea reports positive top-line 12-month Phase 2b data for GEN-003 in genit..


 







 





Financials ($)
 




            Sales             2017            
1,88 M 

            EBIT             2017            
-55,8 M 

            Net income             2017            
-57,2 M 

            Finance 2017            
61,2 M 

            Yield             2017            
- 





            P/E ratio 2017            
            -            

            P/E ratio 2018            


            
            EV / Sales 2017            
            
59,9x 

            EV / Sales 2018
            
6,61x 

            Capitalization            
            
174 M 



More Financials
 



Chart GENOCEA BIOSCIENCES INC




Duration : 
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.



Period : 
Day
Week 





 






Full-screen chart

 

Technical analysis trends GENOCEA BIOSCIENCES INC
 
Short TermMid-TermLong TermTrendsBullishNeutralBullish 

Technical analysis


Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts. 
More Financials


Consensus


                        Sell
                   








Buy
                   


 

Mean consensus

    OUTPERFORM    
Number of Analysts

    5    
Average target price

21,3 $ 
Spread / Average Target

249% 


Consensus details
 





EPS Revisions 
Please enable JavaScript in your browser's settings to use dynamic charts. 
More Estimates Revisions


Managers
 





 NameTitleWilliam D. Clark
President, Chief Executive Officer & Director
Katrine S. Bosley
Chairman
Jonathan Michael Poole
Chief Financial Officer & Head-Investor Relations
Jessica Baker Flechtner
Chief Scientific Officer
Seth V. Hetherington
Chief Medical Officer
 
More about the company


Sector and Competitors


1st jan.Capitalization (M$)

GENOCEA BIOSCIENCES INC47.82%176





INCYTE CORPORATION32.36%28 093

QUINTILES IMS HOLDINGS INC20.58%19 791

LONZA GROUP41.51%18 096

CELLTRION, INC.--.--%12 524

ALKERMES PLC-1.22%8 819


More Results
 




 



























4-traders.com :MarketsNewsAnalysisStock PicksPortfoliosScreenersWatchlistsTop / FlopToolsOur ServicesAbout :Surperformance SASContact usAdvertiseLegal informationsAbout usStay Connected :FacebookTwitterPartners :Börse: Aktien, Kurse und NachrichtenBest tweets 




   Copyright © 2017 Surperformance. All rights reserved.  









 


  














Slave







Genocea Biosciences : cooper ronald harold wilfred | 4-Traders















































































 




Log in






E-mail



Password







Remember




Forgot password ?









Become a member for free
Sign up





Sign up




New memberSign up for FREE


New customerDiscover our portfolios












 United States
 United Kingdom
 France
 Deutschland
 Schweiz (DE)
 Suisse (FR)










Settings

            Dynamic quotes 


OFFON








 








Markets
Equities
North AmericaEuropeAsiaOceaniaMiddle East» More Equities

Indexes
DOW JONESS&P 500NASDAQ 100TSX COMPFTSE 100» More Indexes

Currency / Forex
EUR / USDGBP / USDUSD / JPYUSD / CADAUD / USD» More Currencies

Commodities
GOLDCrude Oil (WTI)Crude Oil (BRENT)SILVERPLATINUM» More Commodities


 News
Latest News
CompaniesMarketsEconomyCurrency / ForexCommoditiesInterest RatesBusiness LeadersFinancial calendarEconomic calendar

Listed company
Analyst reco.RumorsIPOsCapital Markets TransactionsNew ContractsProfits warningsAppointmentsPress ReleasesEventsCorporate actions

Sector News
EnergyBasic MaterialsIndustrialsConsumer CyclicalConsumer Non-CyclicalFinancialsHealthcareTechnologyTelecommunications ServicesUtilities


 Analysis
All AnalysisCommentariesIndex AnalysisStock Trading StrategiesCommodity AnalysisForex Analysis

 Stock Picks
All stock picks

 Portfolios
My Portfolio
Virtual portfolios
4-Traders Portfolios
European PortfolioUSA PortfolioAsian Portfolio


 Screeners
Market Screener HomeFundamental Analyse
Top Investor RatingTop Trading RatingTop ConsensusGrowth stocksYield stocksLow valuations

Technical Analysis
Oversold stocksOverbought stocksClose to resistancesClose to supportsAccumulation phaseMost volatile stocks


 Watchlists
My Watchlists
Watchlists
Top Lists
Yield stocksGrowth stocksUndervalued Stocks


 Top / Flop
Top News
Most Read NewsHot News

Top Fundamentals
Top CapitalizationTop YieldTop PERTop ConsensusTop Fundamentals

Top Technicals
Top RSIUnusual volumesTop GapsTop STIM

Top Movers
Top USATop CanadaTop U.K.Top GermanyTop EuropeTop Asia


 Tools
Market ScreenerDynamic chartFinancial calendarEconomic calendarSector researchCurrency converter

 Our Services
Premium AccessDiscover our Services

 



















 







4-Traders Homepage  >  Equities  >  Nasdaq  >  Genocea Biosciences Inc    GNCA










     GENOCEA BIOSCIENCES INC (GNCA)     


Add to my list    

Mes dernières consult.Most popular
Manage my lists

















 







 Delayed  - 07/27 10:00:00 pm

6.09
USD
 
-1.30%










07/25 GENOCEA BIOSCIE : Reports Positive Top-Line 12-Month Phase 2b Data f..


07/25 INSIDER TRADING : GNCA) – CFO Sold 45,000 shares of Stock


07/24 GENOCEA BIOSCIE : current report

 







SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions News SummaryMost relevantAll newsSector newsTweets


















 




Genocea Biosciences : cooper ronald harold wilfred



































0






06/14/2016 | 10:49pm CEST 


Send by mail :
Last Name :
Name :
From* :
To* :
(You can enter multiple email addresses separated by commas)
Message :
*Required fields








FORM 3





OMB APPROVAL OMB Number: 3235-0104 Estimated average burden
             hours per response... 0.5








1. Name and Address of Reporting Person 

Cooper Ronald Harold Wilfred



2. Date of Event Requiring Statement (MM/DD/YYYY) 

3. Issuer Name and Ticker or Trading Symbol

GENOCEA BIOSCIENCES, INC. [GNCA]




C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR



4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) 


CAMBRIDGE, MA 02410



5. If Amendment, Date Original Filed (MM/DD/YYYY) 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
               ___ Form filed by More than One Reporting Person





1.Title of Security
               (Instr. 4)


2. Amount of Securities Beneficially Owned
               (Instr. 4)


3. Ownership Form: Direct (D) or Indirect (I)
               (Instr. 5)


4. Nature of Indirect Beneficial Ownership
               (Instr. 5)




1. Title of Derivate Security
               (Instr. 4)


2. Date Exercisable and Expiration Date(MM/DD/YYYY)


3. Title and Amount of Securities Underlying Derivative Security
               (Instr. 4)


4. Conversion or Exercise Price of Derivative Security


5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
               (Instr. 5)


6. Nature of Indirect Beneficial Ownership
               (Instr. 5)


Date Exercisable


Expiration Date


Title


Amount or Number of Shares


Explanation of Responses:


Remarks: 
            Exhibit List - Exhibit 24 Power of Attorney
          

            No securities are beneficially owned.
          

Reporting Owners 

Reporting Owner Name / Address




Director


10% Owner


Officer


Other


Cooper Ronald Harold Wilfred
             C/O GENOCEA BIOSCIENCES, INC.
             100 ACORN PARK DRIVE 5TH FLOOR
             CAMBRIDGE, MA 02410


X








Signatures 

/s/ Jonathan Poole, Attorney-in-Fact




6/14/2016


Signature of Reporting Person


Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.


*


If the form is filed by more than one reporting person, see Instruction 5(b)(v).


**


Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).


Note:


File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.


Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.




Genocea Biosciences Inc. published this content on 14 June 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on  14 June 2016 20:49:07 UTC.
          


Original documenthttp://ir.genocea.com/secfiling.cfm?filingID=1676880-16-3&CIK=1457612
Public permalinkhttp://www.publicnow.com/view/B65CB86D7613FD939CE3D6AA82CAAEC20E153108























































0






 






Latest news on GENOCEA BIOSCIENCES INC




07/25 GENOCEA BIOSCIENCES INC : Todays Research Reports on Trending Tickers: Genocea ..

07/25 GENOCEA BIOSCIENCES : Reports Positive Top-Line 12-Month Phase 2b Data for GEN-0..

07/25 INSIDER TRADING ACTIVITY GENOCEA BIO : GNCA) – CFO Sold 45,000 shares of S..

07/24 GENOCEA BIOSCIENCES : current report

07/24 GENOCEA BIOSCIENCES, INC. (NASDAQ : GNCA) Files An 8-K Regulation FD Disclosure

07/24 GENOCEA BIOSCIENCES : Reports Positive Top-Line 12-Month Phase 2b Data for GEN-0..

07/24 GENOCEA BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and E..

07/24 Genocea Reports Positive Top-Line 12-Month Phase 2b Data for  GEN-003 in Geni..

06/26 Genocea Added to Russell 3000® and Russell 2000® Indices

06/15 GENOCEA BIOSCIENCES : current report



More news




News from SeekingAlpha




07/25 Genocea Biosciences's (GNCA) Conference Call On Positive GEN-003 Phase 2b Res..

07/25 PREMARKET GAINERS AS OF 9 : 05 am

07/24 BIOTECH FORUM DAILY DIGEST : Dynavax Technologies' Moment Of Truth Arrives

07/24 PREMARKET GAINERS AS OF 9 : 05 am

07/24 Genocea reports positive top-line 12-month Phase 2b data for GEN-003 in genit..


 







 





Financials ($)
 




            Sales             2017            
1,88 M 

            EBIT             2017            
-55,8 M 

            Net income             2017            
-57,2 M 

            Finance 2017            
61,2 M 

            Yield             2017            
- 





            P/E ratio 2017            
            -            

            P/E ratio 2018            


            
            EV / Sales 2017            
            
59,9x 

            EV / Sales 2018
            
6,61x 

            Capitalization            
            
174 M 



More Financials
 



Chart GENOCEA BIOSCIENCES INC




Duration : 
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.



Period : 
Day
Week 





 






Full-screen chart

 

Technical analysis trends GENOCEA BIOSCIENCES INC
 
Short TermMid-TermLong TermTrendsBullishNeutralBullish 

Technical analysis


Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts. 
More Financials


Consensus


                        Sell
                   








Buy
                   


 

Mean consensus

    OUTPERFORM    
Number of Analysts

    5    
Average target price

21,3 $ 
Spread / Average Target

249% 


Consensus details
 





EPS Revisions 
Please enable JavaScript in your browser's settings to use dynamic charts. 
More Estimates Revisions


Managers
 





 NameTitleWilliam D. Clark
President, Chief Executive Officer & Director
Katrine S. Bosley
Chairman
Jonathan Michael Poole
Chief Financial Officer & Head-Investor Relations
Jessica Baker Flechtner
Chief Scientific Officer
Seth V. Hetherington
Chief Medical Officer
 
More about the company


Sector and Competitors


1st jan.Capitalization (M$)

GENOCEA BIOSCIENCES INC47.82%176





INCYTE CORPORATION32.36%28 093

QUINTILES IMS HOLDINGS INC20.58%19 791

LONZA GROUP41.51%18 096

CELLTRION, INC.--.--%12 524

ALKERMES PLC-1.22%8 819


More Results
 




 



























4-traders.com :MarketsNewsAnalysisStock PicksPortfoliosScreenersWatchlistsTop / FlopToolsOur ServicesAbout :Surperformance SASContact usAdvertiseLegal informationsAbout usStay Connected :FacebookTwitterPartners :Börse: Aktien, Kurse und NachrichtenBest tweets 




   Copyright © 2017 Surperformance. All rights reserved.  









 


  














Slave















Cooper Ronald Harold Wilfred - Genocea Biosciences Insider Transactions | TipRanks   





Go ProLogin / Sign Up Follow✓Get Real Time TransactionsInsider DetailsCooper Ronald Harold WilfredGenocea Biosciences (GNCA)Director Not RankedCooper Ronald Harold Wilfred's PerformanceCooper Ronald Harold Wilfred has not reported any informative transactions and therefore cannot be ranked.How are Insiders Ranked? Cooper Ronald Harold Wilfred's Trading Historybased on Form 4 Follow✓Get Real Time TransactionsCompany NameInsider PositionHolding ValueLast TransactionLast Transaction  AmountLast Transaction DateGNCAGenocea BiosciencesDirector-DEL_BIODBiodel Inc--See All Insider Trading from Today >You May Also LikeMeet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.Related LinksHow can I benefit from Insider Trading? >See the Top 25 Corporate Insiders >Go to Hot Stocks by Insiders >Find which stocks Insiders traded today >Become a TipRanks MemberGet the best Investing Tips & Hacks straight to your emailFree MembershipSubmitInsider Trading Daily NewsletterProfessional day-trading strategy based on predictive insider transactionsAnnual Return: +85.42%Learn More >Powered by
























